6.3.1.9 Glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonists
Tirzepatide is approved for treating type 2 diabetes in line with NICE TA924. For specialist initiation with specialist defined as secondary care prescribers, GPs, Specialist DSNs, and specialist pharmacists or nurses in primary care (e.g. practice or spoke nurses) who have completed PITstop or equivalent.
Prescribing tirzepatide for weight loss is not clinically supported or funded by Kent and Medway ICB until NICE have evaluated its use for this indication.
Expand All / Expand All (incl. cost)
Tirzepatide is approved for treating type 2 diabetes in line with NICE TA924. For specialist initiation with specialist defined as secondary care prescribers, GPs, Specialist DSNs, and specialist pharmacists or nurses in primary care (e.g. practice or spoke nurses) who have completed PITstop or equivalent.
Prescribing tirzepatide for weight loss is not clinically supported or funded by Kent and Medway ICB until NICE have evaluated its use for this indication.
| Pack | Price |
|---|---|
| 1 pre-filled disposable injection | £92.00 |
| Pack | Price |
|---|---|
| 1 pre-filled disposable injection | £92.00 |
| Pack | Price |
|---|---|
| 1 pre-filled disposable injection | £107.00 |
| Pack | Price |
|---|---|
| 1 pre-filled disposable injection | £107.00 |
| Pack | Price |
|---|---|
| 1 pre-filled disposable injection | £122.00 |
| Pack | Price |
|---|---|
| 1 pre-filled disposable injection | £122.00 |